Bruker has formed a new, single division out of the various spatial biology assets it has acquired over the years. | Bruker ...

Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. | Capricor ...

Alaunos Therapeutics is axing an agreement with Precigen, giving up licensing rights to a personalized T-cell platform. | ...

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...

Eli Lilly is ramping up its efforts to incorporate AI across its business by appointing Thomas Fuchs to the new role of chief ...

In order to focus its resources on the phase 1 program, dubbed TIDAL-01, the company has today announced a reduction in staff ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the ...

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

Difficult. Impossible. Agonizing. Worse than voting in the national election. | Difficult. Impossible. Agonizing. Worse than ...

To find RNA viruses hiding in genomic “dark matter,” researchers took advantage of one thing they all have in common: the RNA polymerase enzyme.

The digital diabetes developer Glooko has collected $100 million and a new CEO to help boost the trajectory of its data ...

Ono Pharmaceutical has bought a seat in a quiet corner of the congested antibody-drug conjugate (ADC) space, agreeing | Ono ...